Ribavirin (CED0001627)

Ribavirin belongs to the triazole ribonucleosides and ribonucleotides, a class of nucleosides, nucleotides, and analogues within the organic compounds. It has the chemical formula C8H12N4O5 and an average molecular weight of 244.20 g/mol. This compound is utilized as a drug (PMC6950311) and an antiviral drug (PMC7161744). It acts as an antagonist/inhibitor of RNA-directed RNA polymerase L, RNA-directed RNA polymerase catalytic subunit (PB1), Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1), and the genome polyprotein, among other recorded protein targets. Ribavirin is used in the treatment of Lassa fever (PMC7125859), inflammation (PMC1513604), and COVID-19 (PMC8451976). Additionally, it has demonstrated a therapeutic effect on breast cancer (PMC12644199) and COVID-19 (PMC7381292). The compound is found in or released from 17 recorded sources. These include healthcare, pharmaceuticals and veterinary products such as antibiotics and antivirals; food, food processing and cookware, specifically the preparation of malt; household cleaning and consumer products including pipe accessories, other smoking requisites, non electric simulated smoking devices, cigar cigarettes; and electrical and electronic equipment including magnets, line transmission systems, electrically stimulated smoking devices, antennas, and amplifiers. Recorded exposure routes for Ribavirin include oral, intravenous, respiratory, subcutaneous, and inhalation, with the latter supported by literature (PMC6259602).